Lattermann A, Schoppet M, Mueller-Eckhardt G
Institut für Klinische Immunologie und Transfusionsmedizin, Justus-Liebig-Universität Giessen, Deutschland.
Beitr Infusionsther Transfusionsmed. 1994;32:256-60.
For one year we determined HLA class II antigens from all patients with renal and haematological disorders and their healthy family members both by using serological methods and DNA typing (SSO, SSP). The rate of discrepancies between the results of serological DR typing and DRB1 typing was 10.8% (13/120). We were able to demonstrate that DNA typing for class II antigens leads to definite results even for patients with a poor cell quality or with lymphocytopenia where serological typing is often impossible. Furthermore, DNA typing from patients with haematological disorders is very important, especially if a bone marrow transplantation is considered. In addition to MLC testing, DRB1, DQB1 and DPB1 typing should be carried out for the patient and the potential donor. DNA typing is also recommended for patients waiting for a kidney transplantation particularly if they were serologically typed as 'homozygous', as the chance to receive an HLA-compatible organ is much higher for a heterozygous individual.
在一年的时间里,我们通过血清学方法和DNA分型(序列特异性寡核苷酸探针杂交法、序列特异性引物聚合酶链反应法),对所有患有肾脏疾病和血液系统疾病的患者及其健康家庭成员进行了HLA - II类抗原检测。血清学DR分型结果与DRB1分型结果之间的差异率为10.8%(13/120)。我们能够证明,即使对于细胞质量差或淋巴细胞减少的患者,血清学分型往往无法进行,但II类抗原的DNA分型仍能得出明确的结果。此外,对患有血液系统疾病的患者进行DNA分型非常重要,尤其是在考虑进行骨髓移植的情况下。除了混合淋巴细胞培养试验外,还应对患者和潜在供体进行DRB1、DQB1和DPB1分型。对于等待肾脏移植的患者,也建议进行DNA分型,特别是当他们血清学分型为“纯合子”时,因为杂合个体接受HLA配型相合器官的机会要高得多。